Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991 | 0.78 | TSHR (0.48) | TSHRALDH1A1ENPP2CYP1A2CYP2A6 | |
| SCHEMBL29352520 | 0.78 | TSHR (0.48) | TSHRALDH1A1ENPP2CYP1A2CYP2A6 | |
| SCHEMBL4129 | 0.77 | TSHR (0.47) | TSHRALDH1A1ENPP2LMNA | |
| SCHEMBL29404220 | 0.77 | TSHR (0.47) | TSHRALDH1A1ENPP2LMNA | |
| SCHEMBL28937384 | 0.77 | ALDH1A1 (0.54) | TSHRALDH1A1CYP1A2CYP2A6 | |
| SCHEMBL28963359 | 0.77 | CYP1A2 (0.50) | TSHRALDH1A1CYP1A2CYP2A6 | |
| 2,6-Dichlorophenol SCHEMBL8986495 | 0.76 | TSHR (0.50) | TSHRALDH1A1HSP90AA1IDO1CYP1A2 | |
| SCHEMBL1772196 | 0.76 | ALDH1A1 (0.48) | TSHRALDH1A1ENPP2CYP1A2CYP2A6 | |
| 2,6-Dichlorophenol SCHEMBL65234 | 0.76 | — | — | |
| SCHEMBL132727 | 0.75 | ALDH1A1 (0.55) | ALDH1A1ENPP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250359473-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERAL DISPLAY CORPORATION (US) | 2025-11-20 | — | — | US | disclosed |
| US-12453280-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4446327-B1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEMICAL LTD (KR) | 2025-09-24 | — | — | EP | disclosed |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| EP-4605388-A1 | <SUP2/>? <SUB2/>?3?2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CXCR1 | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | disclosed |
| EP-4254527-B1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEMICAL LTD (KR) | 2025-07-30 | — | — | EP | disclosed |
| EP-4587127-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2025101738-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20140131663-A1 | Iridium Complexes With Aza-Benzo Fused Ligands | UNIVERSAL DISPLAY CORPORATION (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140131663-A1 | Iridium Complexes With Aza-Benzo Fused Ligands | UNIVERSAL DISPLAY CORPORATION (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140131676-A1 | IRIDIUM COMPLEXES WITH AZA-BENZO FUSED LIGANDS | UNIVERSAL DISPLAY CORPORATION (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140131663-A1 | Iridium Complexes With Aza-Benzo Fused Ligands | UNIVERSAL DISPLAY CORPORATION (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2730583-A1 | Iridium complexes with aza-benzo fused ligands | Universal Display Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730583-A1 | Iridium complexes with aza-benzo fused ligands | Universal Display Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8507512-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2401265-A2 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010099054-A2 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | TSHR 1113/4885ALDH1A1 1531/4885HSP90AA1 2175/4885 |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | TSHR 4388/4885ALDH1A1 2230/4885HSP90AA1 1539/4885 |
| US-12453280-B2 | Organic electroluminescent materials and devices | OCIAD1, OCIAD2, OSBP | TSHR 4121/4885ALDH1A1 434/4885HSP90AA1 3875/4885 |
| US-20250359473-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OSBP | TSHR 4128/4885ALDH1A1 497/4885HSP90AA1 3877/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | TSHR 3739/4885ALDH1A1 4095/4885HSP90AA1 1695/4885 |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A1, GUCY1A2 | TSHR 1172/4885ALDH1A1 1356/4885HSP90AA1 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.